RECRUIT-TandAbs: harnessing the immune system to kill cancer cells (Q38024123)

27 August 2017

title

RECRUIT-TandAbs: harnessing the immune system to kill cancer cells (English)

1 reference

27 August 2017

Fionnuala McAleese

1

1 reference

27 August 2017

Markus Eser

series ordinal

2

1 reference

27 August 2017

language of work or name

English

0 references

publication date

1 June 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

8

1 reference

27 August 2017

issue

6

1 reference

27 August 2017

page(s)

687-695

1 reference

Hybrid antibodies can target sites for attack by T cells

27 August 2017

cites work

1 reference

Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies

21 January 2018

1 reference

Engineered proteins pull double duty

21 January 2018

1 reference

Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma.

21 January 2018

1 reference

Bispecific T-cell engaging antibodies for cancer therapy

21 January 2018

1 reference

Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion

21 January 2018

1 reference

Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics

21 January 2018

1 reference

Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site

21 January 2018

1 reference

Chemical generation of bispecific antibodies

21 January 2018

1 reference

Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules

21 January 2018

1 reference

Cancer Imaging and Therapy with Bispecific Antibody Pretargeting

21 January 2018

1 reference

DARPins and other repeat protein scaffolds: advances in engineering and applications

21 January 2018

1 reference

Adnectins: engineered target-binding protein therapeutics

21 January 2018

1 reference

Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities

21 January 2018

1 reference

DARPins: a new generation of protein therapeutics.

21 January 2018

1 reference

Bispecific antibodies for cancer immunotherapy: Current perspectives

21 January 2018

1 reference

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

21 January 2018

1 reference

Novel Monoclonal Antibodies for Cancer Treatment: The Trifunctional Antibody Catumaxomab (Removab®)

21 January 2018

1 reference

Structural and functional characterization of the trifunctional antibody catumaxomab

21 January 2018

1 reference

The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

21 January 2018

1 reference

A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity

21 January 2018

1 reference

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

21 January 2018

1 reference

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

21 January 2018

1 reference

MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors

21 January 2018

1 reference

"Diabodies": small bivalent and bispecific antibody fragments

21 January 2018

1 reference

Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies.

21 January 2018

1 reference

Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody

21 January 2018

1 reference

Modulation of antibody effector function

21 January 2018

1 reference

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

21 January 2018

1 reference

Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia

21 January 2018

1 reference

Hodgkin’s lymphoma: current treatment strategies and novel approaches

21 January 2018

1 reference

Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma

21 January 2018

1 reference

Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases

21 January 2018

1 reference

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 January 2018

1 reference

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma.

21 January 2018

1 reference

T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab.

21 January 2018

1 reference

Immunosuppressive mechanisms in cancer: consequences for the development of therapeutic vaccines.

21 January 2018

1 reference

Update on anti-CTLA-4 antibodies in clinical trials

21 January 2018

1 reference

Immunosuppressive strategies that are mediated by tumor cells

21 January 2018

1 reference

Hierarchical role of CD3 chains in thymocyte development

21 January 2018

1 reference

CD3-specific antibodies: a portal to the treatment of autoimmunity

21 January 2018

1 reference

Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma

21 January 2018

1 reference

Generation of bispecific and tandem diabodies

21 January 2018

1 reference

Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.12.54

1 reference

27 August 2017

1 reference